The World Asthma and COPD Treatment Market, 2006-2011: A Changing Market with Increasing Potential

Questions: Discounts, Updates etc.

Pages: 137

Price (Single): £1,499

Price (Departmental): £2,999

Price (Company): £4,999

Publication Date: 2006-08-24

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *


VISIONGAIN'S LATEST REPORT – ORDER YOUR COPY TODAY

The asthma treatment market is a $15 billion market, driven by an increasing prevalence and yet without a treatment to cure this debilitating disease. All current drugs treat the symptoms but not the underlying cause. It is currently dominated by GSK with its $5.5 billion blockbuster, Advair/Seretide. However, this combination treatment is about to have its first real competition with Symbicort approved for the US market in July 2006. Combination drugs appear likely to dominate the mid-term forecast period as assessed by visiongain.

Pivotal Period
However, a closer look at the potential for this market sees an approaching pivotal period, which could well see considerable change as well as additional growth. New companies are developing products with novel modes of action. The monoclonal antibodies, for so long heralded as the most significant advance the pharmaceutical industry has developed in a number of years, appear to be ready to fulfill their potential in the asthma market.

Concern
Yet there are concerns. There is currently only one available mAb for asthma treatment – Xolair. It is more expensive than other asthma drugs and is only used for patients who have difficult to control asthma. Yet the standard drug treatments are also under examination. Concern over the overuse of steroid treatments has been compounded by recent revelations of possible safety concerns over the long-term use of beta-2 agonist reliever treatments.

The dominant company in this market is GSK but it may see its position slip as new drug treatments enter the market.

Why you should buy this report:

  • The asthma treatment market is large and is set to grow further.
  • Generic competition is already having an impact and will having further impetus after the market-leading drug Advair/Seretide loses patent protection in 2008.
  • By the end of the forecast period the leading companies will be competing with novel products.
  • Monoclonal antibodies look set to achieve their potential in a market that has significant unmet needs.
  • Leading drugs in the principal R&D based company pipelines are assessed.
  • This report considers the latest financial and anecdotal information to enable the most appropriate choice of strategy for this market.

Table of Contents

 

  • List of Tables and Figures
  • Table 1.1 Blockbuster Drugs in the World Asthma and   COPD Treatment Market
  • Table 2.1  Asthma and COPD Compared
  • Table 2.2 Prices of Major Asthma Drugs, 2006
  • Table 3.1  Revenue ($m) of Blockbuster Drugs in the   World Asthma and COPD Treatment Market
  • Table 3.2  World Revenues ($m) for the Leading   Asthma and COPD Drugs, by Class, 2005-  2011
  • Table 3.3  World Market Revenue ($m) and Market   Share (%) for the Classes of Asthma and   COPD Drugs, 2005 and 2011
  • Table 4.1  World Revenues ($m) For Combination Class  Treatments, 2005-2011
  • Table 4.2  Patent Expiry for Combination Treatments,   2006
  • Table 5.1  World Revenues ($m) for Leukotriene   Inhibitors, 2005-2011
  • Table 5.2  Patent Expiry for the Leukotriene Inhibitors,   2006
  • Table 6.1  Patent Expiry for Corticosteroid Class   Treatments, 2006
  • Table 6.2  World Revenues ($m) for Corticosteroid   Class Treatments, 2005-2011
  • Table 7.1  World Revenues ($m) for the Beta-2    Agonists, 2005-2011
  • Table 7.2 Patent Expiry for the Beta-2 Agonists, 2006
  • Table 8.1  World Revenues ($m) for the Mast Cell   Stabilisers, 2005-2011
  • Table 8.2  Patent Expiry for the Mast Cell Stabilisers,   2006
  • Table 9.1  World Revenues ($m) for Monoclonal   Antibodies, 2004-2011
  • Table 9.2  Patent Expiry for the Monoclonal Antibodies,  2006
  • Table 10.1  Pipeline Drugs for Asthma Treatment, 2006
  • Table 10.2  Pipeline Drugs for COPD Treatment, 2006
  • Table 10.3  Pipeline Products, Vectura, 2006
  • Table 11.1  Estimated Asthma Potential Patient    Population, 2005
  • Table 11.2  Estimated Revenues ($m) For Asthma   Treatment Drugs By Country and World   Market Share (%), 2005
  • Figure 1.1  Market Share (%) for the Asthma and COPD   Treatment Market by Company, 2005
  • Figure 1.2  Growth in Revenue ($m) for the World   Asthma and COPD Treatment Market, 2003-  2011
  • Figure 3.1  World Revenue ($m) for the Classes of   Asthma and COPD Drugs, 2005-2011
  • Figure 3.2  World Market Share (%) for Asthma and   COPD Treatments by Class, 2005
  • Figure 3.3  World Market Share (%) for Asthma and   COPD Treatments by Class, 2011
  • Figure 3.4  Change in World Revenue ($m) for Asthma   and COPD Treatment by Class, 2005 and   2011
  • Figure 3.5  Growth (%) of World Revenue of Asthma/   COPD Treatments by Class to 2011
  • Figure 3.6  Market Share (%) for the Asthma and COPD   Treatment Market by Company, 2005
  • Figure 3.7  Market Share (%) for the Asthma and COPD   Treatment Market by Company, 2011
  • Figure 4.1  Revenue ($m) for the Combination Class   Treatments, 2005-2011
  • Figure 4.2  Revenue ($m) for Advair/Seretide, 2003-  2011
  • Figure 4.3  Revenue ($m) for Symbicort, 2004-2011
  • Figure 4.4  Revenue ($m) for Atmadisc, 2004-2011
  • Figure 4.5  World Market Share (%) for the    Combination Drugs, 2005
  • Figure 4.6  World Market Share for the Combination   Drugs, 2011
  • Figure 4.7  World Revenues ($m) for the Combination   Treatments by Drug, 2005-2011
  • Figure 5.1  Revenue ($m) for the Leukotriene    Inhibitors Class Treatments, 2005-2011
  • Figure 5.2  World Market Share (%) for the Leukotriene   Inhibitors, 2005
  • Figure 5.3 World Market Share (%) for the Leukotriene   Inhibitors, 2011
  • Figure 5.4  Revenue ($m) for Singulair, 2003-2011
  • Figure 5.5  Revenue ($m) for Onon, 2004-2011
  • Figure 5.6  Revenue ($m) for Accolate, 2003-2011
  • Figure 5.7  World Revenues ($m) for the Leukotriene   Inhibitors by Drug, 2005-2011
  • Figure 6.1  World Revenues ($m) for Corticosteroid   Class Treatments, 2005-2011
  • Figure 6.2  World Market Share (%) for the    Corticosteroids, 2005
  • Figure 6.3  World Market Share (%) for the    Corticosteroids, 2011
  • Figure 6.4  Revenue ($m) for Pulmicort, 2004-2011
  • Figure 6.5  Revenue ($m) for Flovent/Flixotide, 2004-  2011
  • Figure 6.6  Revenue ($m) for Azmacort, 2004-2011
  • Figure 6.7  Revenue ($m) for Qvar, 2004-2011
  • Figure 6.8  World Revenue ($m) for Corticosteroid   Treatments by Drug, 2005-2011
  • Figure 7.1  World Revenue ($m) for the Beta-2 Agonist   Class, 2005-2011
  • Figure 7.2  Serevent Revenue ($m), 2004-2011
  • Figure 7.3  Foradil Revenue ($m), 2004-2011
  • Figure 7.4  Oxis Revenue ($m), 2004-2011
  • Figure 7.5  Ventolin Revenue ($m), 2003-2011
  • Figure 7.6  World Market Share (%) for the Beta-2   Agonists, 2005
  • Figure 7.7  World Market Share (%) for the Beta-2   Agonists, 2011
  • Figure 7.8  World Revenues ($m) for the Beta-2    Agonists by Drug, 2005-2011
  • Figure 8.1  Intal Revenue ($m), 2004-2011
  • Figure 9.1  Revenue ($m) for the Monoclonal Antibody   Class Treatments, 2005-2011
  • Figure 9.2  Revenue ($m) for Xolair, 2004-2011
  • Figure 11.1  Estimated Asthma Potential Patient    Populations for the Leading Pharmaceutical   Markets, 2005
  • Figure 11.2  Revenue ($bn) for Asthma Treatment Drugs   by Country, 2011

    •  

    Other users found this report page using the following search terms: asthma copd emphysema respiratory bronchitis airway asthma market patent seretide copd expiry treatment advair drug world

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.